Liquid biopsies analyze blood, urine, or sputum for DNA signatures of cancer, and can detect many cancers earlier than current screening protocols. The technology is still developing, but could radically transform cancer diagnosis and treatment.
Catch screening recommendations are informed by near-term risk. Although your lifetime risk for a particular cancer may be elevated, that doesn't mean that near-term screening is always the right decision.